Question 1

Which loses more weight, Wegovy or Qsymia?

Accepted Answer

Wegovy, on the published trial data. In STEP-1 (Wilding 2021 NEJM, PMID 33567185), semaglutide 2.4 mg weekly produced -14.9% body weight at 68 weeks in 1,961 adults with overweight or obesity without diabetes. In EQUIP (Allison 2012 Obesity, PMID 22051941), the top-dose Qsymia 15/92 mg arm produced -10.9% at 56 weeks in 1,267 adults with class II-III obesity. CONQUER (Gadde 2011 Lancet, PMID 21481449) replicated -9.8% at 56 weeks in a less-severe-obesity population. The trials were not head-to-head — different durations, different baseline BMIs, different eras of placebo lifestyle support — so cross-trial gap estimates of roughly 4-5 percentage points should be read with caution, but the directional difference is consistent across populations.

Question 2

Why does Qsymia require a REMS program and Wegovy doesn't?

Accepted Answer

The topiramate component of Qsymia is a known teratogen — first-trimester exposure raises the risk of oral cleft (cleft lip and/or cleft palate) by roughly 2-5×, based on antiepileptic pregnancy registries. The FDA mandated a Risk Evaluation and Mitigation Strategy (REMS) at approval requiring patient counseling, monthly pregnancy testing for patients who can become pregnant, and use of effective contraception throughout treatment. Qsymia is dispensed only through certified mail-order pharmacies that confirm REMS compliance. Wegovy carries pregnancy guidance to discontinue at least 2 months before a planned pregnancy because of the long ~7-day half-life, but no REMS — semaglutide is not classified as a known structural teratogen at human exposures.

Question 3

Is Qsymia cheaper than Wegovy?

Accepted Answer

Yes, by a wide margin. Qsymia Advantage (the manufacturer cash-pay program) lists branded Qsymia in the ~$100-$200/mo range depending on the offer cycle, often with a free first-month trial. Patients who switch to the generic phentermine + topiramate combination (filling each component as a separate generic prescription) can often pay ~$50/mo with GoodRx coupons at retail pharmacies, though the generics are immediate-release topiramate rather than the extended-release formulation in branded Qsymia, which changes the dosing schedule. Wegovy's NovoCare manufacturer cash-pay program is $499/mo, and uninsured retail is roughly $1,350/mo. Insurance coverage of either drug for obesity remains spotty across both commercial and Medicaid plans.

Question 4

Can I take Qsymia if I have a history of kidney stones or depression?

Accepted Answer

Both are caution flags. Topiramate's weak carbonic anhydrase inhibition increases urinary citrate excretion and raises kidney-stone risk, particularly calcium phosphate stones — Qsymia is not strictly contraindicated in patients with stone history, but most prescribers either avoid it or counsel aggressive hydration and consider citrate supplementation. For depression, Qsymia carries the antiepileptic class warning for suicidal behavior and ideation, and topiramate is associated with mood disorders and cognitive complaints; patients with active or recent major depression are typically steered to a different agent (often Wegovy, which has no such warning and which the SELECT trial found did not increase psychiatric adverse events versus placebo). Patients with depression in remission can sometimes start Qsymia with close monitoring.

Question 5

Will Qsymia's cognitive side effects go away?

Accepted Answer

Often partially, but not always fully. The topiramate-driven cognitive complaints — word-finding difficulty, attention and concentration problems, memory impairment, paresthesias — are dose-related and partly reflect time-to-tolerance. In the EQUIP and CONQUER trials, the slow 14-week titration (3.75/23 → 7.5/46 → 11.25/69 → 15/92 mg) was designed specifically to let these adapt; many patients report improvement after 4-8 weeks at a stable dose. Patients whose work depends on rapid verbal fluency, complex problem-solving, or fine motor coordination (surgeons, attorneys, pilots, musicians) often hit a ceiling at the mid-dose 7.5/46 mg level and cannot tolerate the maximum dose, which caps the weight loss they can expect. Wegovy does not produce this cognitive side-effect profile, which is one of the strongest case-by-case reasons to choose it over Qsymia.

Question 6

Can I switch from Qsymia to Wegovy if I stall?

Accepted Answer

Yes, and switching is common — the two drugs have completely different mechanisms (central appetite suppression + GABA/glutamate modulation vs GLP-1 receptor agonism), so failure on one does not predict failure on the other. There is no required washout: phentermine clears in 1-2 days and topiramate in 3-5 days, so most clinicians stop Qsymia and start Wegovy at the standard 0.25 mg weekly titration the following week. Prior authorization for Wegovy after Qsymia is generally straightforward because most commercial step-therapy protocols accept an FDA-approved anti-obesity medication trial as the prerequisite. The reverse switch (Wegovy → Qsymia) is also clinically reasonable but slower, because Wegovy's ~7-day half-life means semaglutide is still on board for 5-7 weeks after discontinuation.

Field	Wegovy	Qsymia
Pivotal weight loss	-14.9% body weight at 68 weeks (STEP-1, Wilding 2021)	-10.9% body weight at 56 weeks (EQUIP top-dose 15/92 mg, Allison 2012)
Mechanism	Long-acting GLP-1 receptor agonist (~7-day half-life)	Sympathomimetic (phentermine) + anticonvulsant (topiramate ER) — central appetite suppression + GABA/glutamate modulation
Route and frequency	Once-weekly subcutaneous injection	Once-daily oral capsule (morning)
Cardiovascular outcome	MACE -20% in SELECT (Lincoff 2023, obesity without diabetes)	No dedicated CVOT; small dose-related resting heart rate increase (+1.6 bpm at 15/92 mg)
Cash price (manufacturer programs)	$499/mo via NovoCare manufacturer cash-pay program	~$100-$200/mo via Qsymia Advantage; generic phentermine + topiramate ~$50/mo via GoodRx
REMS / pregnancy prevention	No REMS; pregnancy guidance is to discontinue ≥2 months before conception	REMS-mandatory; monthly pregnancy testing + effective contraception required for patients who can become pregnant (topiramate first-trimester cleft palate risk)
Most common adverse events	Nausea (~44%), diarrhea, vomiting, constipation	Paresthesia, dysgeusia (altered taste), dry mouth, insomnia, cognitive fog (word-finding, attention)
FDA approval	June 2021 (chronic weight management); March 2024 cardiovascular risk reduction	July 2012 (chronic weight management); December 2022 pediatric (12+)
Controlled substance status	Not a controlled substance	Phentermine component is DEA Schedule IV (refill limits, prescription-tracking)
Boxed / class warnings	Boxed warning: thyroid C-cell tumors (rodent data)	Class warnings: suicidal behavior/ideation (antiepileptic class), teratogenicity, acute angle-closure glaucoma

Wegovy vs Qsymia (2026): Injectable GLP-1 vs Oral Pill, Cost, Dosing

The verdict

Side-by-side comparison

Frequently asked questions